Clinical Trial - Trial HKUCTR-2806
Access comprehensive clinical trial information for HKUCTR-2806 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca Hong Kong Limited and is currently Not yet recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
HKUCTR-2806
Phase 3
Not yet recruiting
drug
Trial Details
HKU CLINICAL TRIALS REGISTRY • HKUCTR-2806
Untitled Trial
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)
Study Focus
Sponsor & Location
AstraZeneca Hong Kong Limited
China
Timeline & Enrollment
Phase 3
N/A
Oct 31, 2020
ICD-10 Classifications
Neoplasms
Benign neoplasms
In situ neoplasms
Personal history of other neoplasms
Benign neoplasm: Other specified sites
Data Source
HKU CLINICAL TRIALS REGISTRY
HKUCTR-2806
Non-Device Trial